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Combined 17α-hydroxylase/17,20-
lyase deficiency due to p.R96W 
mutation in the CYP17 gene 
in a Brazilian patient
Deficiência combinada de 17α-hidroxilase/17,20 liase devido à 
mutação p.R96W no gene CYP17 em um paciente brasileiro
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SUMMARY
Congenital adrenal hyperplasia (CAH) resulting from 17α-hydroxylase/17,20-lyase deficiency is 
a rare autosomal recessive disease and the second most common form of CAH in Brazil. We 
describe the case of a Brazilian patient with CYP17 deficiency (17α-hydroxylase/17,20-lyase de-
ficiency) caused by a homozygous p.R96W mutation on exon 1 of the CYP17 gene, an unusual 
genotype in Brazilian patients with this form of CAH. The patient, raised as a normal female, 
sought medical care for lack of pubertal signs and primary amenorrhea at the age of 16 years. At 
evaluation, the presence of a 46,XY karyotype, hypertension and hypokalemia were observed. 
We emphasize the recognition of CYP17 deficiency in the differential diagnosis of cases of hy-
pergonadotrophic hypogonadism and hypertension in young patients who need specific treat-
ment for both situations. Arq Bras Endocrinol Metab. 2010;54(8):744-8
SUMÁRIO
A hiperplasia adrenal congênita (HAC), em razão da deficiência de 17α-hidroxilase/17,20-liase, 
é uma doença autossômica recessiva rara e a segunda causa mais comum de HAC no Brasil. 
Descrevemos o caso de um paciente brasileiro portador da deficiência 17α-hidroxilase/17,20- 
liase (CYP17) em homozigose para a mutação p.R96W no éxon 1 do gene da CYP17A1, uma 
mutação incomum entre os casos brasileiros descritos com essa forma de HAC. Esse paciente, 
criado como um indivíduo normal do sexo feminino, procurou atendimento por ausência de si-
nais puberais e amenorreia primária aos 16 anos de idade. Durante a avaliação, constataram-se 
um cariótipo 46,XY e a presença de hipertensão e hipocalemia. Enfatizamos o reconhecimento 
da deficiência da CYP17 dentre os possíveis diagnósticos em um paciente jovem com hipogo-
nadismo hipergonadotrófico e hipertensão, os quais necessitam de tratamento particularizado 
para ambas as situações. Arq Bras Endocrinol Metab. 2010;54(8):744-8
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IntROdUctIOn
Congenital adrenal hyperplasia (CAH) resulting from 17α-hydroxylase/17,20-lyase deficiency is 
an uncommon autosomal recessive disease. The hu-
man 17α-hydroxylase (CYP17) gene is a single copy 
gene located on chromosome 10q24.3-q25 (1) that 
consists of 8 exons spanning 6,569 bases and encod-
ing a protein of 508 amino acids (2). This protein is 
an enzyme expressed in the adrenal cortex and the 
gonads. Cytochrome P450 steroid 17α-hydroxylase 
(P450c17) catalyzes both the 17α-hydroxylation of 
pregnenolone and progesterone and also the 17,20-ly-
ase reaction of 17α-hydroxypregnenolone/17α-
hydroxyprogesterone to produce the C-19 steroid 
precursors of androgens and estrogens, dehydroepi-
androsterone (DHEA) and androstenedione. Genetic 
abnormalities in the CYP17 gene affect both adrenal 
and gonadal steroidogenesis.
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The 17α-hydroxylase/17,20-lyase deficiency is as-
sociated with impaired production of cortisol and sex 
steroids leading to an elevation of plasma ACTH and 
overproduction of mineralocorticoids other than al-
dosterone resulting in hypertension, hypokalemia, and 
bilateral adrenal hyperplasia. In addition, the impaired 
production of sex steroids leads to abnormal sexual de-
velopment. Therefore, this deficiency is clinically char-
acterized by hypertension, hypokalemia, and sexual ab-
normalities such as 46,XY disorder of sex development 
(DSD) or sexual infantilism in 46,XX females (3-6).
In fact, 17α-hydroxylase/17,20-lyase deficiency 
seems to be the second most common form of CAH 
in Brazil (4,7). An founder effect may also contribute 
to the high prevalence of CYP17 deficiency in Brazil, 
although the Brazilian population is among the most 
ethnically heterogeneous in the world (8). Previously, 
30 Brazilian subjects with 17α-hvdroxylase deficiency 
from 24 kindred were reported and seven CYP17 gene 
mutations were reported in this sample (9). Recently, a 
new mutation of 25 bp duplication at exon 5 of CYP17 
was described in two Brazilian sisters (46,XY kariotype), 
with the classical clinical presentation of this enzymatic 
defect and with P450c17 molecular modeling predicting 
the loss of both enzymatic activities of this protein (10). 
Herein, we report the second case of 
17α-hydroxylase/17,20-lyase deficiency in a Brazilian 
patient caused by a homozygous p.R96W mutation in 
the CYP17 gene and the fifth case in world literature.
cASe RePORt
A phenotypically female Brazilian patient presented at 
16 years of age with lack of pubertal signs and primary 
amenorrhea. Her parents were consanguineous from 
Portuguese and Italian ancestry.
On physical examination her skin was darker than 
her parents. Recumbent blood pressure was elevated at 
150 x 115 mmHg. Height was 151 cm and weight was 
36,5 kg; arm span, inferior, and superior segments were 
163 cm, 83 cm, and 68 cm, respectively. Tanner stage 
was B1P1, with an infantile female external genitalia 
and a blind vagina. Routine lab results showed normal 
sodium levels, BUN and creatinine; low serum potassi-
um (3.3 mEq/L) and undetectable plasma renin activ-
ity (< 0.2 ng/mL/h); other results are shown in table 1. 
Her bone age was delayed (11 years), while the chrono-
logical age was 15 years/ 9 month-old (SD = 9.23 mo). 
Karyotype was 46,XY and uterus and gonads were not 
CYP17, congenital adrenal hyperplasia
table 1. Baseline biochemistry and hormone values in plasma
Results normal range values
Cortisol 8h (µg/dL) 1.8 6.2-19.4
17α-OHP (ng/dL) 18 31-217
Estradiol (pg/mL) < 5 7.5-42.5
LH (mUI/mL) 60.1 1.7-8.6
FSH (mUI/mL) 46.6 1.5-12.4
Total testosterone (ng/mL) < 0.1 3.5-25
Progesterone (ng/mL) 6.14 0.2-1.4
DHEAS (µg/dL) 2 25-250
Androstenedione (ng/dL) < 11 5-35
ACTH (pg/mL) 476 10-52
K (mEq/L) 3.2 3.5-5.1
Bicarbonate (mEq/L) 30 22-30
Aldosterone (ng/dL) 29 Supine: 2.9-16.2
PRA (ng/mL/h) < 0.20 Upright: 0.98-4.18
17α-OHP: 17α-hydroxyprogesterone; PRA: plasma renin activity. 
visualized on an abdominal-pelvic US. Patient’s height 
was below calculated family target (172 cm for a boy 
although bone age was delayed).
Serum levels of 17α-OHP, DHEA-S, androstenedi-
one and cortisol were low, whereas aldosterone, ACTH 
and progesterone were elevated. A cosyntropin stimula-
tion test added evidence to the diagnosis revealing un-
detectable and unresponsive levels of cortisol and corti-
sone, 21-deoxycortisol (21DF), 11-deoxycortisol, and 
17α-OHP, in presence of substantially elevated deoxy-
corticosterone (DOC) and corticosterone (Table 2).
Oral prednisolone was started at 5 mg/day without 
appropriate blood pressure and biochemical control; 
an increase to 7.5 mg/day normalized blood pressure 
levels and controlled steroid excess (Table 3). Subse-
quently, the patient was started on transdermic estra-
diol (25 mcg/day) with no interference with blood 
pressure control.
table 2. Basal and ACTH–stimulated adrenal steroid values
Steroids Baseline Post-ActH
normal range values
 Basal  Post-ActH
Cortisol (µg/dL) ND ND  6-25 18-42
Cortisone (ng/dL) ND ND  800 3500
21Deoxycortisol (ng/dL) 26 68  0-40 < 156
11Deoxycortisol (ng/dL) 0.7 4.1  0-45 < 140
17α-OHP (ng/dL) 7 9  < 5  < 10
DOC (ng/dL) 527 612  4-12  12-61
Corticosterone (ng/dL) 18, 377 22, 030  0.1-0.5 1.7-4.8
17α-OHP: 17α-hydroxyprogesterone; DOC: deoxycorticosterone; ND: not done. 
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with the GenBank sequence for CYP17 (accession no. 
M19489) using Mac Vector 6.5.3 (AccelrysCorp. San 
Diego, CA, USA) (12). Identified mutations were con-
firmed by sequencing the product of a second PCR am-
plification in the opposite direction (Figure 1). Parental 
DNA was not available for investigation. 
table 3. Biochemistry and hormonal values after prednisone 7.5 mg/day 
Prednisolone 
7.5 mg/day
 estradiol 
25 µg/day
normal 
range values
Cortisol 8h (µg/dL) 2.8 1.13 6.2-19.4
17α-OHP (pg/mL) 0.18 - 0.31-2.17
Progesterone (ng/mL) 0.28 1.31 0.2-1.4
DHEAS (µg/dL) 1.9 - 24.4-247
Androstenedione (ng/dL) < 0.11 - 0.5-3.5
ACTH (pg/mL) < 10 990 10-52
K (mEq/L) 5.6 4.5 3.5-5.1
Bicarbonate (mEq/L) 28 28 22-30
Aldosterone (ng/dL) 8.2 22.8 Supine: 
2.9-16.2
PRA (ng/mL/h) 1.15 - Upright: 
0.98-4.18
17α-OHP: 17α-hydroxyprogesterone; PRA: plasma renin activity. 
Genomic DNA was extracted from peripheral leuko-
cytes and all eight exons of the CYP17 gene were ampli-
fied by PCR (see below). The two most common muta-
tions identified in Brazilian patients were not found in 
our patient; instead, an p.R96W (in exon 1) in homozy-
gosis was detected. Neither her parents, nor her brother 
were hypertensive and their hormonal profile of serum 
progesterone, sex and adrenal steroids, gonadotropin, 
sodium and potassium were in the normal range. 
dnA PRePARAtIOn, PcR, And SeqUencIng 
DNA was extracted from peripheral leukocytes by a 
standardized salting out procedure (11). The 6.4-kb 
CYP17 gene was amplified into 1-4 pieces from 0.5-1 
µg genomic DNA using TaKaRa Ex Taq DNA poly-
merase (Takara Shuzo Co., Shiga, Japan) in 100 µL re-
actions using buffer and deoxy-NTPs provided by the 
manufacturer and 3% dimethylsulfoxide. To amplify 3- 
to 4-kb products, PCR parameters included 40 cycles of 
3 min at 94°C, 1 min at 65°C, and 3 min at 70°C. An-
nealing time was increased to 1.5 min for amplification 
of the entire gene and the extension parameters were 
72°C for 5.5 min. The final PCR products were precipi-
tated with ethanol and purified on 1% agarose gels us-
ing the QIAEX II kit (Qiagen, Chatsworth, CA, USA). 
Amplicons were submitted to direct sequencing of the 
8 exons and flanking intronic DNA by the dye termina-
tion method on a PE Applied Biosystems instrument 
(McDermott Center Sequencing Facility at University 
of Texas Southwestern Medical Center, Dallas, TX, 
USA). The mutations were identified by comparison 
Figure 1. Electropherogram of p.R96W mutation with a transition C → T 
in codon Arg 96 (CGG) into a Trp (TGG) in exon 1.
dIScUSSIOn 
The p.R96W mutation has been reported rarely in 
CYP17: in two 46,XY DSD French-Canadian siblings 
presenting with combined 17α-hydroxylase/17,20-
lyase deficiency (12), an Italian patient (13) and also in 
another Brazilian patient (14). Our 16-year old patient 
sought treatment for delayed puberty and during clini-
cal examination her blood pressure levels were elevated. 
Very often P450c17 deficiency remains undiagnosed 
until adolescence or early adulthood: overproduction 
of corticosterone substitutes for low cortisol produc-
tion and prevents an adrenal crisis. Cortisol impairment 
results in secondary ACTH oversecretion and adrenal 
stimulation to produce large amounts of DOC which 
leads to clinical manifestations of mineralocorticoid ex-
cess: increased renal tubular resorption of sodium and 
kaliuresis, producing hypertension, hypokalemia and 
suppressed plasma renin activity (6). Thus, the adrenal 
zona glomerulosa does not receive renin stimulation 
for aldosterone synthesis, resulting in reduced aldo-
sterone secretion (7). However, this is not the case in 
all 17OHD patients, and some, as our patient, present 
serum hyperaldosteronism, the reason of which is still 
unclear and; possibilities include: a disorder of ste-
roidogenesis and/or regulation or a cross-reaction be-
tween aldosterone and some other increased steroid(s) 
(5,14-15). The purpose of replacement glucocorticoid 
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therapy is to suppress the ACTH stimulation of zona 
fasciculata reducing the mineralocorticoid excess, and 
controlling hypertension and hypokalemia.
When combined 17α-OH and 17,20-lyase deficien-
cies are present, both the adrenal and gonadal produc-
tion of sex steroids are impaired, leading to hypergo-
nadotropic hypogonadism in both genetic sexes (7,16). 
Thus, replacement therapy with oral estrogen is nec-
essary, running the risk that hypertension may be ag-
gravated; this is possibly due to activation of estrogen 
receptors in the adrenal cortex, that may stimulate the 
altered mineralocorticoid’s synthetic route in CYP17 
deficient patients (17). Estrogen replacement was start-
ed in our patient with a transdermal 17b-estradiol for-
mulation (25 µg/day). As expected, with the lack of 
first-pass hepatic metabolism and reduced GI enzymatic 
catabolism, the therapeutic effects could be achieved at 
lower peak doses and less impact on disease control. In 
fact, our patient’s blood pressure did not change on this 
replacement scheme; however, elevation of ACTH, pro-
gesterone and aldosterone levels were observed togeth-
er with a slight reduction of cortisol levels. This replace-
ment schedule may also interact with steroidogenesis, 
but with no significant effect on blood pressure levels.
Structural modeling suggests that R96 lies within 
the flanking strand 2 of b-sheet 1, and the guanidine 
group of R96 appears to form hydrogen bonds with 
carbonyl groups of residues A113 and F114 (18). Re-
moval of this positively charged group, which occurs in 
p.R96W mutation, appears to instabilize the protein by 
disrupting this interaction between the two domains, 
leading to complete enzyme inactivation (3).The sever-
ity of clinical disease tends to be milder with mutations 
that retain a partial catalytic activity (7,19), but the 
age of onset of hypertension, the degree of hypokale-
mia, and aldosterone production rate appear to vary, 
even among patients with the same CYP17 mutations 
(10,15). Patients with partial 17α-hydroxylase defi-
ciency can have ambiguous genitalia at birth (7,15,19). 
Recently a patient was described who carried both 
p.R96W and missense H373D mutation on the CYP17 
gene, showing that these mutations cause a dramatic 
loss of both enzymatic P450c17 activities (20). The 
missense p.R96W mutation causes a transition C→ T 
in codon Arg 96 (CGG) into a Trp (TGG) in exon 1 
(12) (Figure 1), abolishing almost completely the activ-
ity of the mutant protein (3,20).
The p.R96W mutation can be explained by a found-
er effect, since our patient was from southern Brazil, an 
area traditionally under European migratory influence 
and whose population is more of a Caucasian ethnic-
ity. The fact that founder effects can be manifested in a 
country with great ethnic heterogeneity also suggests a 
high coefficient of inbreeding in local areas.
Interestingly, CYP17 deficiency is the second most 
frequent form of CAH in Brazil (5,8), but to the best 
of our knowledge, the p.R96W mutation, has been 
identified just for the second time in Brazil. However, 
it is possible that the prevalence of this mutation may 
be higher than reported , especially in southern Brazil, 
a major German and Italian ethnic extract. 
Disclosure: no potential conflict of interest relevant to this article 
was reported.
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